{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T10:56:43Z","timestamp":1791284203821,"version":"4.1.0"},"reference-count":60,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The plethora of pharmacologic treatments used for periorificial dermatitis (POD) makes clinical decision\u2010making challenging. The objectives of this review were to assess the efficacy and safety of pharmacological interventions for POD in children and adults. The search was performed on 2 February 2021 and included seven databases and trial registries, with no date or language restrictions Study selection, data extraction and risk of bias assessments were performed independently and in duplicate by two authors, in accordance with a prespecified protocol. Meta\u2010analyses were performed and reported in accordance with PRISMA guidelines. Where meta\u2010analysis was not possible, a narrative synthesis was performed and reported in accordance with SWiM guidelines. The certainty of evidence was assessed using the Grading of Recommendation, Assessment, Development and Evaluation approach. Eleven studies representing 733 participants were included. Oral tetracycline may improve physician\u2010reported severity of POD from day 20 onwards (low certainty evidence). Adverse effects may include abdominal discomfort, facial dryness and pruritus. Pimecrolimus cream may improve physician\u2010reported severity slightly after 4\u2009weeks of treatment (MD \u22120.49, 95% CI \u22121.02 to 0.04, <jats:italic>n<\/jats:italic>\u2009=\u2009164, low certainty evidence). Adverse effects may include erythema, herpes simplex virus infection, burning and pruritus. Azelaic acid gel may result in no change in either physician\u2010 or patient\u2010reported severity after 6\u2009weeks of treatment. The evidence is very uncertain about the effect of praziquantel ointment on physician\u2010reported severity and skin\u2010related quality of life after 4\u2009weeks of treatment. The evidence is also very uncertain about the effect of topical clindamycin\/benzoyl peroxide on physician\u2010reported severity. The body of evidence to inform treatment of POD currently consists of low and very low certainty evidence for important outcomes. Well\u2010designed trials are needed to further investigate treatment options. Data are required for children and from low\u2010middle income countries to improve external validity. Future trials should also include adequate post\u2010treatment follow\u2010up and standardized outcome measures.<\/jats:p>","DOI":"10.1111\/jdv.17817","type":"journal-article","created":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T09:11:28Z","timestamp":1636967488000},"page":"380-390","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7024-3903","authenticated-orcid":false,"given":"N.A.","family":"Gray","sequence":"first","affiliation":[{"name":"Division of Dermatology Department of Medicine Tygerberg Academic Hospital and Stellenbosch University Cape Town South\u00a0Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Tod","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Tygerberg Academic Hospital and Stellenbosch University Cape Town South\u00a0Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rohwer","sequence":"additional","affiliation":[{"name":"Centre for Evidence Based Health Care (CEBHC) Division of Epidemiology and Biostatistics Department of Global Health Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Fincham","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics Department of Global Health Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.I.","family":"Visser","sequence":"additional","affiliation":[{"name":"Division of Dermatology Department of Medicine Tygerberg Academic Hospital and Stellenbosch University Cape Town South\u00a0Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"McCaul","sequence":"additional","affiliation":[{"name":"Centre for Evidence Based Health Care (CEBHC) Division of Epidemiology and Biostatistics Department of Global Health Faculty of Medicine and Health Sciences Stellenbosch University Cape Town South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"e_1_2_8_2_1","first-page":"385","article-title":"Pediatric periorificial dermatitis","volume":"100","author":"Kellen R","year":"2017","journal-title":"Cutis"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2006.05.031"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-4362.2003.01852.x"},{"key":"e_1_2_8_5_1","first-page":"611","volume-title":"Dermatology","author":"Powell F","year":"2018"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-014-0067-7"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.064"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15695"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.12534"},{"key":"e_1_2_8_10_1","unstructured":"Bayer HealthCare. A 6\u2010week vehicle\u2010controlled randomized double\u2010blind parallel\u2010group multicentre pilot study of the efficacy and safety of azelaic acid (AzA) 15% gel in the topical treatment of mild to moderate perioral dermatitis 2012. URL https:\/\/www.cochranelibrary.com\/central\/doi\/https:\/\/doi.org\/10.1002\/central\/CN\u201001834712\/full (last accessed: 2 February 2021)."},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2019.31.S.S27"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/ced.12342"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2012.11.022"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.13969"},{"key":"e_1_2_8_15_1","first-page":"179","article-title":"Perioral dermatitis: still a therapeutic challenge","volume":"54","author":"Mokos ZB","year":"2015","journal-title":"Acta Clin Croat"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1159\/000084754"},{"key":"e_1_2_8_17_1","unstructured":"GrayN VisserW RohwerA McCaulM&TodBPharmacological Interventions for Periorificial (Perioral) dermatitis in children and adults: a systematic review protocol. PROSPERO 2020 CRD42020219743 2020. URLhttps:\/\/www.crd.york.ac.uk\/prospero\/display_record.php?ID=CRD42020219743(last accessed 30 Mar 2021)."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l6890"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_8_20_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.1","author":"Reeves B","year":"2020"},{"key":"e_1_2_8_21_1","unstructured":"Veritas Health Innovation. Covidence systematic review software. URL www.covidence.org (last accessed: 2 February 2021)."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2007.02191.x"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/09546639309084514"},{"key":"e_1_2_8_27_1","unstructured":"Review Manager (RevMan) [Computer program]. Version 5.4. The Cochrane Collaboration 2020."},{"key":"e_1_2_8_28_1","unstructured":"Relative risk calculator. URLhttps:\/\/www.medcalc.org\/calc\/relative_risk.php(last accessed: 12 June 2021)."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/9781119536604.ch10"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(91)70038-4"},{"key":"e_1_2_8_31_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2","author":"McKenzie J","year":"2021"},{"key":"e_1_2_8_32_1","unstructured":"Evidence Prime I. GRADEpro GDT: Guideline Development Tool [Software] 2020. URL gradepro.org (last accessed: 15 June 2021)."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/ebmed-2017-110668"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.2336\/nishinihonhifu.41.129"},{"key":"e_1_2_8_35_1","first-page":"139","article-title":"34th Annual Meeting of the European Society for Dermatological Research: Vienna, September 9\u201011, 2004","volume":"13","author":"Kansky A","year":"2004","journal-title":"Acta Dermatovenerol Alp Pannon Adriat"},{"key":"e_1_2_8_36_1","first-page":"66","article-title":"The treatment of perioral dermatitis with tetracycline and metronidazole","volume":"29","author":"Korolev YUF","year":"1983","journal-title":"Zdravookhr Beloruss"},{"key":"e_1_2_8_37_1","unstructured":"Sanz\u2010MotilvaV Martorell\u2010CalatayudA HuesoL PelufoC Garc\u00eda\u2010MelgaresML AlfaroA.POO14 Steroid\u2010induced perioral dermatitis treated with topical ivermectin and oral doxycycline. In: 25th EADV Congress 2016."},{"key":"e_1_2_8_38_1","first-page":"410","article-title":"Steroid rosacea (perioral dermatitis)","volume":"62","author":"Deichmann B","year":"1986","journal-title":"Z Allgemeinmed"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1973.tb129696.x"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2014.26.4.462"},{"key":"e_1_2_8_41_1","first-page":"127","article-title":"[Metronidazole therapy in rosacea (author\u2019s transl)]","volume":"106","author":"Guilhou JJ","year":"1979","journal-title":"Ann Dermatol Venereol"},{"key":"e_1_2_8_42_1","first-page":"46","article-title":"Perioral dermatitis. Study of 22 cases","volume":"23","author":"Gutierrez RM","year":"1979","journal-title":"Dermatologia Rev Mex"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1159\/000424239"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2002.00392_4.x"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.06202.x"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajd.12344"},{"key":"e_1_2_8_47_1","first-page":"527","article-title":"\u201cTherapy\u201d of so\u2010called perioral dermatitis","volume":"22","author":"R\u00f6ckl H","year":"1971","journal-title":"Hautarzt"},{"key":"e_1_2_8_48_1","first-page":"253","article-title":"Value of tetracycline therapy in perioral dermatitis","volume":"24","author":"Schubert E","year":"1973","journal-title":"Hautarzt"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.1998.tb01304.x"},{"key":"e_1_2_8_50_1","first-page":"55","article-title":"Perioral dermatitis","volume":"34","author":"Coskey RJ","year":"1984","journal-title":"Cutis"},{"key":"e_1_2_8_51_1","unstructured":"DraelosZ. Clindamycin\/benzoyl peroxide in the treatment of perioral dermatitis: A double\u2010blind randomized vehicle controlled study.J Am Acad Dermatol2006;543 Suppl:AB85."},{"issue":"2","key":"e_1_2_8_52_1","first-page":"12","article-title":"Photodynamic therapy for perioral dermatitis","volume":"5","author":"Richey DF","year":"2006","journal-title":"J\u2009Drugs Dermatol"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.03.043"},{"key":"e_1_2_8_54_1","unstructured":"Novartis PharmaA 4 week randomized vehicle\u2010controlled multicenter evaluation of the efficacy and safety of 1% pimecrolimus cream in adult patients with perioral dermatitis followed by a 8 week treatment free observation phase in responders \u2013 PERIDEL 2005. URL http:\/\/www.who.int\/trialserch\/Trial2.aspx?TrialID=EUCTR2005\u2010002058\u201023\u2010DE (last accessed: 2 February 2021)."},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.10.058"},{"key":"e_1_2_8_56_1","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.2","author":"Sterne J","year":"2021"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1554-3"},{"key":"e_1_2_8_58_1","unstructured":"AlamM SobankoJ MaherI CarteeTCochrane skin core outcome set for Rosacea 2020. URL http:\/\/cs\u2010cousin.org\/rosacea\/ (last accessed 18 May 2021)."},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-152-11-201006010-00232"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1525-1470.2009.00979.x"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.008"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17817","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.17817","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.17817","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T02:43:30Z","timestamp":1693104210000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.17817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":60,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1111\/jdv.17817"],"URL":"https:\/\/doi.org\/10.1111\/jdv.17817","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]},"assertion":[{"value":"2021-08-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-03","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}